Close Menu

NEW YORK – Three investment banks on Monday initiated coverage of rare disease genetic testing and services company Centogene with bullish outlooks.

BTIG initiated coverage of Rostock, Germany-based Centogene with a Buy rating on its stock and an $18 price target, while SVB Leerink rated the firm's shares Outperform and put a price target of $21. Evercore ISI began coverage of Centogene with an Outperform rating on its stock and a $17 price target.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.